Inventor · disambiguated record
Andrew Mercer
Also filed as: MERCER ANDREW · MERCER ANDREW A · MERCER ANDREW ALLAN
8 granted patents·14 pending applications·47 citations·filing 1999–2023
85Inventor score
Top patents by PatentIndex Score
22 records- 0187US9902962B2Chimeric polypeptides having targeted binding specificitySCRIPPS RESEARCH INST·Filed 2013·Granted Feb 27, 2018·7 cites·9 claims
- 0283US9314505B2Combination treatments and compositions for wound healing comprising viral VEGFWISE LYN MARIE·Filed 2013·Granted Apr 19, 2016·16 cites·31 claims
- 0380US10829766B2Chimeric polypeptides having targeted binding specificitySCRIPPS RESEARCH INST·Filed 2018·Granted Nov 10, 2020·1 cites·15 claims
- 0478US8357363B2Recombinant proteins of parapoxvirus ovis and pharmaceutical compositions therefromAICURIS GMBH & CO KG·Filed 2002·Granted Jan 22, 2013·5 cites·4 claims
- 0576US2023304022A1Chimeric polypeptides having targeted binding specificitySCRIPPS RESEARCH INST·Filed 2022·Application pending·0 cites
- 0670US11466277B2Chimeric polypeptides having targeted binding specificitySCRIPPS RESEARCH INST·Filed 2020·Granted Oct 11, 2022·0 cites·10 claims
- 0769US9714272B2Recombinant proteins of parapdxvirus ovis and pharmaceutical compositions therefromAICURIS GMBH & CO KG·Filed 2014·Granted Jul 25, 2017·0 cites·11 claims
- 0869US2019292231A1Recombinant proteins of parapoxvirus ovis and pharmaceutical compositions therefromAICURIS GMBH & CO KG·Filed 2019·Application pending·0 cites
- 0965US2025249127A1Gene therapy for treating an ocular diseaseREGENXBIO INC·Filed 2023·Application pending·0 cites
- 1062US2017320918A1Recombinant proteins of parapoxvirus ovis and pharmaceutical compositions therefromAICURIS GMBH & CO KG·Filed 2017·Application pending·0 cites
- 1161US8852577B2Recombinant proteins of Parapoxvirus ovis and pharmaceutical compositions therefromAICURIS GMBH & CO KG·Filed 2012·Granted Oct 7, 2014·0 cites·10 claims
- 1261US6541008B1Vascular endothelial growth factor-like protein from orf viruses binds and activates mammalian VEGF receptor-2, and uses thereofUNIV OTAGO·Filed 1999·Granted Apr 1, 2003·18 cites·17 claims
- 1361US2025277004A1Hybrid aav capsidsREGENXBIO INC·Filed 2023·Application pending·0 cites
- 1456US2025001006A1Recombinant adeno-associated viruses for targeted deliveryREGENXBIO INC·Filed 2022·Application pending·0 cites
- 1555US2025179518A1Recombinant adeno-associated viruses for cns tropic deliveryREGENXBIO INC·Filed 2022·Application pending·0 cites
- 1654US2024218397A1Novel aav vectors and methods and uses thereofREGENXBIO INC·Filed 2022·Application pending·0 cites
- 1753US2023381341A1Adeno-associated viruses for ocular delivery of gene therapyREGENXBIO INC·Filed 2021·Application pending·0 cites
- 1852US2025326861A1Vectorized lanadelumab and administration thereofREGENXBIO INC·Filed 2021·Application pending·0 cites
- 1951US2023374541A1Recombinant adeno-associated viruses for cns or muscle deliveryREGENXBIO INC·Filed 2021·Application pending·0 cites
- 2044US2022186256A1Recombinant adeno-associated viruses and uses thereofREGENXBIO INC·Filed 2020·Application pending·0 cites
- 2142US2003211101A1Vascular endothelial growth factor-like protein from ORF viruses binds and activates mammalian VEGF receptor-2, and uses thereofFiled 2003·Application pending·0 cites
- 2240US2016263191A1Combination Treatments and Compositions for Wound HealingOTAGO INNOVATION LTD·Filed 2016·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →